TLX250-CDx aims to address unmet needs in ccRCC imaging, with a potential U.S. commercial launch in 2025. The FDA's initial concerns were related to sterility assurance, not the agent's safety or ...
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD. BCG monotherapy remains the preferred first-line treatment for ...
FDA BCG-unresponsive criteria include CIS recurrence within 12 months or high-grade Ta/T1 recurrence within 6 months after ≥7 BCG doses, shaping access to newer agents. AUA guidance continues to ...
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups. Updated CAPItello-281 data showed a ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
The Edison System uses histotripsy, a non-invasive ultrasound technology, to treat kidney tumors without surgery, radiation, or systemic therapies. The #HOPE4KIDNEY trial enrolled 67 patients with non ...
The deep PSA responses with the darolutamide regimen were found to be correlated with improved overall survival and a prolonged time to PSA progression. The addition of darolutamide (Nubeqa) to ...
"We’ve achieved a lot, but the focus now must shift from cure alone to comprehensive, patient-centered care," says Vladimir Hugec, MD.
Pre-operative counseling should frame vasectomy as intended permanent contraception, individualized to reproductive goals, and can be delivered virtually or in person while directly addressing ...
CMS issued a J-code for Anktiva, effective January 1, 2025, aiding billing and reimbursement processes for intravesical therapies. Anktiva, approved by the FDA in April 2024, is used with BCG for ...
LiSWT and PRP independently and combined significantly improved IIEF scores in ED treatment compared to control therapy. LiSWT was the most effective standalone treatment, with a mean IIEF score ...